All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CD20 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD20. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD20 antibody linked to 41BB and CD3ζ signaling domains. And the vector product was designed for the treatment of NHL.
CAR Construction : Fig.1 Analysis of antibody binding to CD20 + CHO by whole cell ELISA. Antibody reactivity to CD20 + CHO fixed on a PLL plate was tested. Nishida, M., Usuda, S., Okabe, M., Miyakoda, H., Komatsu, M., Hanaoka, H., ... & Niwa, O. (2007). Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab). International journal of oncology, 31(1), 29-40. |
CAR Construction : Fig.2 The anti-CD20 binding activity of CD20-binding polypeptide compositions and immunocytokines. Human Daudi lymphoma cells were incubated with varying concentrations of polypeptide compositions and ICs and relative binding to the cells was assessed by flow cytometry. Carr, F. J., Williams, S., & Gillies, S. D. (2012). U.S. Patent No. 8,147,832. Washington, DC: U.S. Patent and Trademark Office. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD20 (2B8) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-YF820). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION